Reported Saturday, GSK Announced RUBY Phase III Data Show Potential For Jemperli (Dostarlimab-Gxly) Combinations In More Patients With Primary Advanced Or Recurrent Endometrial Cancer
Portfolio Pulse from Benzinga Newsdesk
GSK announced that Phase III data for Jemperli (dostarlimab-gxly) combinations show significant potential in treating primary advanced or recurrent endometrial cancer. The combination of dostarlimab-gxly and chemotherapy demonstrated a 31% reduction in risk of death and a 16.4-month improvement in overall survival compared to chemotherapy alone. Additionally, adding Zejula (niraparib) to dostarlimab-gxly maintenance after chemotherapy showed a 37% reduction in risk of disease progression or death and a 6-month improvement in progression-free survival in the MMRp/MSS population.
March 18, 2024 | 6:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's announcement of positive Phase III data for Jemperli in treating endometrial cancer could positively impact its stock price due to the potential for increased revenue from this new treatment option.
The announcement of positive Phase III data for a cancer treatment typically leads to positive investor sentiment, as it indicates potential for new revenue streams from the treatment's market approval and sales. Given the significant improvements in survival rates demonstrated by Jemperli, this could be particularly impactful for GSK.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100